BIOLIFE4D Proceeding on Mission to Bioprint Human Hearts, Taps Regenerative Biomaterials Expert Adam W. Feinberg, Ph.D. to Lead Scientific Advisory Team



CHICAGO, Nov. 13, 2017 /PRNewswire/ -- Biotech pioneer BIOLIFE4D is reporting significant progress in its quest to become the first company to bioprint a fully functional and transplantable human heart, tapping regenerative medicine and biomedical engineering veteran Adam W. Feinberg, Ph.D. to lead its accomplished Scientific Advisory Team.

"BIOLIFE4D is focused and working incredibly hard, putting the right talent and technology in place to be first to market with a commercially viable 3D bioprinting process for complete human organs - and Dr. Feinberg is precisely the right person to head up our science and medical team," said BIOLIFE4D CEO Steven Morris. "His expertise, leadership and dedication are invaluable as we drive toward our specific goal of bioprinting human hearts - creating a new paradigm of life-saving care that will give patients the gift of time."

In addition to his new role at BIOLIFE4D, Feinberg is Associate Professor of Materials Science & Engineering and Biomedical Engineering at Carnegie Mellon University (CMU) and Principal Investigator of the Regenerative Biomaterials and Therapeutics Group. He has vast experience developing materials-based engineering strategies to control the self-organization and assembly of various cell types into tissues - a foundational requirement to successfully bioprint human organs.

BIOLIFE4D is a new, equity crowdfunded company focused on making human organ replacement commonplace globally using an approach that combines recent breakthroughs in regenerative medicine, stem cell biology, 3D printing techniques and computing technology.

BIOLIFE4D seeks to optimize a process that will capitalize on the growing number of milestones that have been reached in the field of 3D bioprinting recently. For example, in May CNN reported that a collaboration of scientists including BIOLIFE4D's Ramille Shah, Ph.D. implanted a 3D bioprinted ovary in an infertile mouse that allowed it to mate naturally and give birth to live pups.

Feinberg, who will work closely with Shah and others on the BIOLIFE4D science team, earned his BS in Materials Science and Engineering, with an option in bioengineering, from Cornell University with co-op experience working on total artificial hearts.

He also received a MS and Ph.D. in Biomedical Engineering from the University of Florida, and completed his postdoctoral training at Harvard University in the School of Engineering and Applied Sciences, where he developed new biomaterials and cardiac tissue engineering strategies for three-dimensional myocardial regeneration, with a focus on stem cell-based approaches.

Feinberg presented at the 47th World Economic Forum Annual Meeting has been the recipient of numerous awards and recognition, including the National Institutes of Health Director's New Innovator Award, the George Tallman Ladd Faculty Research Award (Carnegie Institute of Technology, CMU), and the National Science Foundation CAREER Award.

"I am excited to be part of BIOLIFE4D as the company works to make transplant-grade 3D bioprinted organs a reality," said Feinberg. "Focused research and development is foundational to accelerating the clinical translation and commercialization of these technologies. We have an exceptional Scientific Advisory Team that CEO Steve Morris has assembled, with world-class expertise across science, engineering and medicine."

In addition to Shah, Feinberg's colleagues at BIOLIFE4D include Ibrahim Ozbolat, Ph.D. from Penn State University, Sean Palecek, Ph.D. from the University of Wisconsin at Madison, Shayn Peirce-Cottler, Ph.D. from the University of Virginia, Raimond Winslow, Ph.D. from Johns Hopkins University and Janet Zoldan, Ph.D. from the University of Texas in Austin. In addition, Jeffrey Morgan M.D., FACS, FACC, an accomplished thoracic and cardiac surgeon from the Texas Heart Institute, joined BIOLIFE4D as Chief Medical Officer.

BIOLIFE4D has filed a $50 million initial public offering with the Securities and Exchange Commission (SEC) under Regulation A+ equity crowdfunding rules, allowing everyday investors to help the company bring its groundbreaking cardiac tissue regeneration and organ replacement process to market. The "Reg A+" rules, outlined under the 2012 Jumpstart Our Business Startups (JOBS) Act, allow companies to raise up to $50 million in equity from non-accredited investors and others.

To learn more about BIOLIFE4D and to express interest in investing visit


BIOLIFE4D is a pioneering biotech company laser focused on leveraging advances in life sciences and tissue engineering to 3D bioprint a viable human heart suitable for transplant - lifesaving technology that gives patients the gift of time. With BIOLIFE4D, a patient-specific, fully functioning heart will be created through 3D bioprinting using the patient's own cells - eliminating the well-known challenges of organ rejection and long donor waiting lists that plague existing organ transplant methods. Financed through equity crowdfunding, BIOLIFE4D is driving a movement to transform the treatment of heart disease, the leading cause of death among both men and women globally. Learn more and invest at Follow us on social media @BIOLIFE4D.

Although you are currently able to express your interest in investing, BIOLIFE4D Corporation is not yet accepting investments. No money or other consideration is being solicited by the company at this time, and if sent in response, will not be accepted. No offer to buy the securities can be accepted and no part of the purchase price can be received until the offering statement is qualified, and any such offer may be withdrawn or revoked, without obligation or commitment of any kind, at any time before notice of its acceptance given after the qualification date. If you indicate interest, your indication of interest involves no obligation or commitment of any kind.

Press Contact:

Consociate Media for BIOLIFE4D
Brian Harris
(804) 815-8377

View original content:



Back to news